Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Financial performance shows a reduction in operating expenses, which is positive, but the company's limited cash reserves and reliance on milestone-based financing pose significant risks. The enrollment challenges in the NEPHRO study are being addressed, but supply chain issues and regulatory risks remain concerns. The Q&A session reveals optimism about accelerating enrollment but highlights uncertainties around supply chain issues. Overall, the sentiment is balanced, leading to a neutral prediction for the stock price movement in the next two weeks.
Key Financial Performance
Cash Operating Expenses (Q2 2025) $3.7 million compared to $4.3 million for Q2 2024, a decrease of approximately 14%. The decrease was primarily due to reductions in personnel expense and other general and administrative expenses.
Cash Operating Expenses Excluding Noncash Stock-Based Compensation (Q2 2025) $3.5 million compared to $4 million for Q2 2024, a decrease of 12.5%. The decrease was primarily due to reductions in personnel expense and other general and administrative expenses.
Cash Balance (June 30, 2025) $6.8 million. This includes proceeds from the first tranche of financing closed on April 2, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nafamostat: Progress in the NEPHRO study with accelerated enrollment rates. The study size was reduced from 166 to 70 patients, and new target profile sites were added. Nafamostat is positioned as a preferred anticoagulant for CRRT if approved, with feedback from investigators supporting its market potential.
Compassionate Use IDE: Advancing discussions with institutions for nafamostat use under compassionate use IDE for patients who do not respond well to other anticoagulants. This highlights a potential market need due to shortages of citrate and heparin.
Operational Efficiency: Cash operating expenses for Q2 2025 were reduced to $3.7 million from $4.3 million in Q2 2024. The 2025 cash operating expense guidance was also lowered to $16-$17 million from $17-$19 million.
Strategic Shifts in Study Design: The NEPHRO study was restructured with a focus on new target profile sites, including nephrologist-led medical ICUs, to improve enrollment rates and study efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical Study Enrollment Challenges: The company faced challenges with low enrollment rates in the NEPHRO study at legacy sites, necessitating a restructuring of the study, including changes to site profiles and principal investigator specialties.
Regulatory Risks: Although the company has a clear regulatory path with FDA breakthrough designation, there is always inherent risk in obtaining final FDA approval for nafamostat.
Supply Chain Risks: The company highlighted potential supply chain issues with heparin and citrate, which could impact the availability of alternative anticoagulants.
Commercial Risks: Despite confidence in nafamostat's market potential, there is always a risk of commercial underperformance due to competition or market adoption challenges.
Financial Constraints: The company is operating with limited cash reserves ($6.8 million as of June 30, 2025) and is reliant on achieving patient enrollment milestones to unlock additional financing tranches.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Completion of NEPHRO Study: The NEPHRO study is expected to be completed by the end of 2025, with accelerated enrollment rates due to changes in study protocols and site profiles.
Expansion of Study Sites: Six new target profile sites are expected to begin enrolling patients in Q3 2025, which will further accelerate the study's progress.
Compassionate Use IDE: The company is advancing a compassionate use IDE submission to the FDA for nafamostat, targeting patients with contraindications to current anticoagulants. No specific timeline for approval has been provided.
Market Potential of Nafamostat: Nafamostat, if approved, is expected to become a primary product for CRRT anticoagulation due to its advantages over current options like heparin and citrate, which face shortages and limitations.
Cash Operating Expense Guidance: The 2025 cash operating expense guidance has been reduced to $16 million to $17 million, down from the previously communicated $17 million to $19 million.
Financial Position: The company expects to secure additional financing through milestone-based tranches, which, combined with current cash reserves, should support operations through the completion of the NEPHRO study by year-end 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the expected acceleration to reach the 70 enrollment target by year-end, given the recent enrollment rate?
A:The rates of enrollment are significantly increasing with new sites enrolling at the same rate or higher. With 9 new sites coming on board within 1.5 months, the target is 55 patients from September to December, requiring about 1.5 patients per site per month. The current run rate is higher than this, and no change in the run rate is expected. The key is getting the sites operational.
Q:Is there an opportunity to leverage data from compassionate use programs for future publication or commercial uptake?
A:Yes, while the data from compassionate use programs will not be part of the efficacy dataset, it will contribute to the safety dataset for submission and be used for publication. This data highlights the use of nafamostat in patients who cannot use heparin or citrate due to specific conditions, addressing an unmet need.
Q:What is the status of heparin and citrate shortages, and when are they expected to resolve?
A:Heparin shortages are episodic and have historical supply chain challenges. Citrate shortages have been reported frequently this year, possibly due to manufacturing or supply chain issues. Both products face unpredictable supply, and users remain concerned about their availability. There is no clear timeline for resolution.
Q:Will the stock price requirement for the second tranche of funding be waived if not met?
A:The investors have the right to waive the stock price requirement. Discussions with investors indicate their primary focus is on achieving the 17-patient milestone rather than the stock price. Waiving the requirement will depend on further discussions.
Q:What are the main components of operating expenses (OpEx), and will there be an increase in the second half of the year?
A:The main components of OpEx include costs related to patient enrollment and trial activities. There will be an increase in OpEx in the second half of the year due to the recent and ongoing increase in enrollment.
Q:What gives confidence that new sites will be operational and enrolling by the end of the third quarter?
A:The new sites have been vetted for their ability to quickly initiate and enroll patients. Historical data and internal benchmarks indicate a 3-4 month timeline for activation. Two of the next six sites have already been activated, and the remaining four are in the final stages of the process. All nine sites are expected to be operational by the end of the quarter.
Q:What has been the main challenge in patient enrollment, and what has driven recent improvements?
A:The main challenge was that the original sites were not well-suited for the study due to their patient populations and focus areas. Recent improvements are driven by shifting to nephrologist-led sites with a better understanding of CRRT and patient needs. The new sites have shown increased consent rates and enrollment due to the enthusiasm and expertise of the investigators.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear answer on the timeline for resolving heparin and citrate shortages, citing general supply chain challenges without specific details or solutions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Angotti CEO
Antonio Eduardo
Arce WestPark
CEO Director
CRRT anticoagulation
CRRT circuit
CRRT shortage
Capital Inc
FDA anticoagulant
IDE institution
Research Division
Talphera Chief
Talphera website
acceleration enrollment
addition study
alternative
announcement
belief
care
closing tranche
efficiency
expense
institution nafamostat
legacy site
market
number patient
proceeds
profile site
protocol change
rate site
reduction
section Talphera
site profile
specialty
study end
study protocol
use IDE
week
TLPH Transcript
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call lacked substantial financial details, with no mention of revenue, margins, or cash flow, making it challenging to assess financial health. The NEPHRO study progress is positive but not enough to drive a strong stock reaction without financial context. The absence of shareholder return discussion and unclear management responses in the Q&A indicate potential uncertainty. Overall, the lack of concrete financial data and strategic insights suggests a neutral sentiment towards stock price movement.
Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call presents a mixed picture: positive aspects include reduced cash operating expenses and potential FDA breakthrough designation, but concerns arise from delayed clinical site activations and dependency on conditional financing. The Q&A reveals further enrollment challenges and unclear management responses. Despite strong market potential for Niyad, commercial risks and uncertainties remain. Without a clear market cap, the overall sentiment is neutral, as positive and negative factors balance each other out.
Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed outlook. Financial performance shows a reduction in operating expenses, which is positive, but the company's limited cash reserves and reliance on milestone-based financing pose significant risks. The enrollment challenges in the NEPHRO study are being addressed, but supply chain issues and regulatory risks remain concerns. The Q&A session reveals optimism about accelerating enrollment but highlights uncertainties around supply chain issues. Overall, the sentiment is balanced, leading to a neutral prediction for the stock price movement in the next two weeks.
Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed outlook. Positive aspects include reduced operating expenses and strategic trial execution plans. However, the lack of specific enrollment numbers and unclear management responses raise uncertainties. The absence of a share repurchase program and financial risks due to limited cash position are concerns. Overall, the sentiment is neutral, as positive trial developments are balanced by uncertainties in enrollment and financial stability.
TLPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
